Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TACR3 | P29371 | 1/20 | 0.46 |
| ▸ | LSS | P48449 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8357171 | 0.92 | KDM4E (0.53) | KDM4ELMNAPTGS2ALDH1A1TACR3 | |
| SCHEMBL8357845 | 0.91 | PTGS2 (0.53) | KDM4EPTGS2ALDH1A1TACR3LSS | |
| SCHEMBL13900061 | 0.83 | LSS (0.55) | KDM4ELMNAPTGS2ALDH1A1LSS | |
| SCHEMBL13900088 | 0.83 | F10 (0.55) | KDM4ELMNAF10MGLL | |
| SCHEMBL8358657 | 0.82 | PTGS2 (0.71) | KDM4EPTGS2ALDH1A1TACR3LSS | |
| SCHEMBL13900123 | 0.80 | PTGS2 (0.59) | KDM4EPTGS2TACR3LSSF10 | |
| SCHEMBL5751986 | 0.79 | MEN1 (0.61) | PTGS2ALDH1A1SMN1; SMN2HTR1AHTR7 | |
| SCHEMBL13900134 | 0.78 | PTGS2 (0.54) | KDM4EPTGS2ALDH1A1F10TSHR | |
| SCHEMBL8358965 | 0.75 | F10 (0.56) | F10 | |
| SCHEMBL13900076 | 0.75 | F10 (0.65) | ALDH1A1F10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451185-B1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | F12, F5, F2 | KDM4E 1568/4885LMNA 577/4885PTGS2 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.